Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit

News

Testosterone Therapy Impedes Diabetes Progress, Study Finds

Mar 26, 2019

At the eight-year point, glucose regulation had returned to normal for 90% of the treatment group. In contrast, 40% of the untreated group had developed type 2 diabetes.

The men who received testosterone saw improvements with their fasting glucose, cholesterol, and triglyceride levels, but levels worsened for the men in the untreated group.

The men in the testosterone group also had improved scores on the Aging Males’ Symptoms (AMS) scale (an assessment tool used to measure health-related quality of life in aging men) compared to the men who did not undergo testosterone therapy.

Mortality rates and incidence of nonfatal heart attacks were higher for the men in the untreated group.

"Long-term [testosterone therapy] completely prevents prediabetes progression to [type 2 diabetes] in men with hypogonadism and improves glycemia, lipids, and AMS score,” the study authors concluded.

They added, “[Testosterone therapy] holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.”

Resources

Centers for Disease Control and Prevention

“Prediabetes: Your Chance to Prevent Type 2 Diabetes”

(Page last reviewed: June 21, 2018)

https://www.cdc.gov/diabetes/basics/prediabetes.html

Diabetes Care

Yassin, Aksam, et al.

“Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study”

(Abstract. March 2019)

http://care.diabetesjournals.org/content/early/2019/03/04/dc18-2388

HealthDay News via DoctorsLounge.com

“Testosterone Therapy in Hypogonadism Can Prevent Progression to T2DM”

(March 15, 2019)

https://www.doctorslounge.com/index.php/news/pb/87280

Univadis

Tucker, Miriam (Curator)

“Testosterone therapy halts progression to T2D in men with hypogonadism”

(March 13, 2019)

http://univadis.com/player/ymqqvugnw?m=unv_eml_essentials_enl_v4-q42018_20190314&partner=unl&rgid=5pbcznujyqbqzkfhvyprpp&ts=2019031400&o=tile_3_id&utm_source=Retention&utm_medium=newsletter&utm_campaign=unv_eml_essentials_enl_v4-q42018_20190314_03

« Previous 1 2 (page 2 of 2)